Treatment for Oligometastatic Breast Cancer
Official title: Role of Metastases Directed Radiotherapy in Addition to Standard of Care Systemic Treatment in the Management of Extracranial Oligometastatic Breast Cancer
Run by National Cancer Institute, Egypt · NCT06144346 · Data updated 2026-11-12
This study is testing whether adding a special type of radiation therapy to standard treatment can help women with a few metastatic breast cancer spots live longer and feel better.
Quick facts
| Study type | Interventional |
|---|---|
| Ages | 18 Years to 70 Years |
| Sex | Women only |
| Enrollment | 150 (estimated) |
| Sponsor | National Cancer Institute, Egypt Academic / other |
| Drugs / interventions | Radiation |
| Locations | 1 site (Cairo) |
| Status | Recruiting |
| Started | September 20, 2023 |
| Main results expected | August 19, 2025 |
| Study ends | September 20, 2028 |
| Registry record updated | November 22, 2023 |
| Trial ID | NCT06144346 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Ideal candidates are adult female patients aged 18 to 70 with oligometastatic breast cancer and a maximum of 5 extracranial metastatic lesions.
✕Probably not a fit
Patients with widespread metastatic disease or those with brain metastases will not benefit from this study.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This clinical trial evaluates the effectiveness of adding metastases directed therapy, specifically Stereotactic Ablative Radiation Therapy (SABR), to standard systemic treatment in women with oligometastatic breast cancer. Participants will be randomly assigned to receive either standard care alone or standard care plus SABR, with the aim of assessing progression-free survival and quality of life. The study also investigates the safety profile of the combined treatment approach. The trial is conducted at the National Cancer Institute in Cairo, Egypt, focusing on adult female patients with a limited number of metastatic lesions.
Why it matters
Potential benefit: If successful, this approach could significantly improve progression-free survival and quality of life for patients with oligometastatic breast cancer.
How similar studies have gone: Other studies have shown promising results with similar approaches, indicating potential for success in this trial.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * Female patients aged 18 to 70 years. * Pathological evidence of breast cancer, any grade, any T stage. * Radiological (at least) evidence of metastatic activity with maximum number of 5 extracranial lesions. * Performance status ≤ 2 * No pre-existing conditions that may prohibit radiotherapy. Exclusion Criteria: •.Pregnant and lactating women. * Prior radiotherapy to affected site(s) in less than a year. * Active Connective tissue diseases (e.g Rheumatoid Arthritis). * Progression to widespread metastatic disease * Cases with brain metastasis
Where it's running
-
National Cancer Institute
Cairo, Egypt Recruiting
Study contacts
- Study coordinator: Rimoun R Boutrus, M.D.
- Email: rimoun.boutrus@nci.cu.edu.eg
- Phone: +201061056900
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Digital health coaching for cancer survivors
This study is testing whether a digital health coaching program can help cancer survivors feel better and improve their health after finishing treatment.
-
PRT13722 in advanced HR+/HER2- breast cancer
This early study tests PRT13722, by itself and with standard therapies, to see if it is safe and has any signs of activity in adults with HR+/HER2- breast cancer who have progressed on prior treatments.
-
Entinostat with Pyrotinib and Endocrine Therapy in HER2-positive, HR-positive Advanced Breast Cancer after Trastuzumab Failure
This study tests whether adding entinostat to pyrotinib and hormone therapy is safe and helps patients with advanced HR+/HER2+ breast cancer who progressed after trastuzumab.
-
UGT1A1 gene and side effects from certain antibody-drug treatments for advanced breast cancer
This project will test whether common UGT1A1 gene variants explain who gets worse side effects from antibody-drug conjugates (sacituzumab-govitecan, trastuzumab-deruxtecan, or datopotamab-deruxtecan) in adults with advanced breast cancer.
-
Generative AI Education Tool for Breast Cancer Care
Researchers are testing an AI-powered teaching tool to help adults with breast cancer understand their care while receiving treatment from UCSF physicians.
-
Pulsed Electric Field Ablation for Metastatic Breast Cancer
This trial tests a one-time pulsed electric field ablation to treat superficial metastatic breast cancer lesions in adults, guided by imaging.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.